Published in Am J Psychiatry on September 01, 2009
What have we learned about trial design from NIMH-funded pragmatic trials? Neuropsychopharmacology (2010) 1.17
A functional alternative splicing mutation in human tryptophan hydroxylase-2. Mol Psychiatry (2010) 0.83
The development of an RDoC-based treatment program for adolescent depression: "Training for Awareness, Resilience, and Action" (TARA). Front Hum Neurosci (2014) 0.82
The role of 5-HT1A receptors in mediating acute negative effects of antidepressants: implications in pediatric depression. Transl Psychiatry (2015) 0.77
Achieving adolescent adherence to treatment of major depression. Adolesc Health Med Ther (2010) 0.75
Increased response to a 5-HT challenge after discontinuation of chronic serotonin uptake inhibition in the adult and adolescent rat brain. PLoS One (2014) 0.75
Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry (2006) 11.25
Safety and tolerability of methylphenidate in preschool children with ADHD. J Am Acad Child Adolesc Psychiatry (2006) 10.19
Rationale, design, and methods of the Preschool ADHD Treatment Study (PATS). J Am Acad Child Adolesc Psychiatry (2006) 10.00
Stimulant-related reductions of growth rates in the PATS. J Am Acad Child Adolesc Psychiatry (2006) 9.98
Pharmacogenetics of methylphenidate response in preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry (2006) 9.85
Risperidone in children with autism and serious behavioral problems. N Engl J Med (2002) 9.35
The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry (2009) 6.71
The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes. Arch Gen Psychiatry (2007) 3.78
3-year follow-up of the NIMH MTA study. J Am Acad Child Adolesc Psychiatry (2007) 3.33
Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry (2008) 3.30
Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study. Am J Psychiatry (2009) 3.17
Predictors and moderators of acute outcome in the Treatment for Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry (2006) 2.95
Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry (2005) 2.94
Treatment of selective serotonin reuptake inhibitor-resistant depression in adolescents: predictors and moderators of treatment response. J Am Acad Child Adolesc Psychiatry (2009) 2.65
Suicide attempts and nonsuicidal self-injury in the treatment of resistant depression in adolescents: findings from the TORDIA study. J Am Acad Child Adolesc Psychiatry (2011) 2.55
Recent trends in stimulant medication use among U.S. children. Am J Psychiatry (2006) 2.52
The Preschool Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS) 6-year follow-up. J Am Acad Child Adolesc Psychiatry (2013) 2.48
Treatment for Adolescents with Depression Study (TADS): safety results. J Am Acad Child Adolesc Psychiatry (2006) 2.45
Treatment of Resistant Depression in Adolescents (TORDIA): week 24 outcomes. Am J Psychiatry (2010) 2.32
Adolescent substance use in the multimodal treatment study of attention-deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication. J Am Acad Child Adolesc Psychiatry (2013) 2.30
Stimulant medication use in children: a 12-year perspective. Am J Psychiatry (2012) 2.27
Remission and residual symptoms after short-term treatment in the Treatment of Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry (2006) 2.26
The Treatment of Adolescent Suicide Attempters study (TASA): predictors of suicidal events in an open treatment trial. J Am Acad Child Adolesc Psychiatry (2009) 2.13
Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry (2007) 2.03
Which treatment for whom for ADHD? Moderators of treatment response in the MTA. J Consult Clin Psychol (2003) 2.02
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning. J Abnorm Child Psychol (2007) 1.98
Delinquent behavior and emerging substance use in the MTA at 36 months: prevalence, course, and treatment effects. J Am Acad Child Adolesc Psychiatry (2007) 1.98
Cost-effectiveness of treatments for adolescent depression: results from TADS. Am J Psychiatry (2008) 1.86
Cognitive-behavioral therapy for suicide prevention (CBT-SP): treatment model, feasibility, and acceptability. J Am Acad Child Adolesc Psychiatry (2009) 1.85
The Treatment for Adolescents with Depression Study (TADS): methods and message at 12 weeks. J Am Acad Child Adolesc Psychiatry (2006) 1.82
Texas Children's Medication Algorithm Project: update from Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder. J Am Acad Child Adolesc Psychiatry (2007) 1.78
Medication use in US youth with mental disorders. JAMA Pediatr (2013) 1.75
Risperidone and adaptive behavior in children with autism. J Am Acad Child Adolesc Psychiatry (2006) 1.71
Modeled economic evaluation of alternative strategies to reduce sudden cardiac death among children treated for attention deficit/hyperactivity disorder. Circulation (2010) 1.69
Validity of the autism diagnostic interview-revised. Am J Ment Retard (2006) 1.66
Neurocognitive outcomes in the Treatment of Early-Onset Schizophrenia Spectrum Disorders study. J Am Acad Child Adolesc Psychiatry (2012) 1.62
Children's Yale-Brown Obsessive Compulsive Scale modified for pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry (2006) 1.61
Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial. J Am Acad Child Adolesc Psychiatry (2009) 1.55
AACAP 2002 research forum: placebo and alternatives to placebo in randomized controlled trials in pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry (2004) 1.53
Remission and recovery in the Treatment for Adolescents with Depression Study (TADS): acute and long-term outcomes. J Am Acad Child Adolesc Psychiatry (2009) 1.51
Secondary evaluations of MTA 36-month outcomes: propensity score and growth mixture model analyses. J Am Acad Child Adolesc Psychiatry (2007) 1.48
Effects of ethnicity on treatment attendance, stimulant response/dose, and 14-month outcome in ADHD. J Consult Clin Psychol (2003) 1.46
Gastrointestinal symptoms in a sample of children with pervasive developmental disorders. J Autism Dev Disord (2008) 1.46
Observed classroom behavior of children with ADHD: relationship to gender and comorbidity. J Abnorm Child Psychol (2002) 1.45
Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials. J Am Acad Child Adolesc Psychiatry (2003) 1.42
Peer-assessed outcomes in the multimodal treatment study of children with attention deficit hyperactivity disorder. J Clin Child Adolesc Psychol (2005) 1.41
Consensus report on impulsive aggression as a symptom across diagnostic categories in child psychiatry: implications for medication studies. J Am Acad Child Adolesc Psychiatry (2007) 1.36
Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry (2004) 1.34
Assessing medication effects in the MTA study using neuropsychological outcomes. J Child Psychol Psychiatry (2006) 1.34
Parent-reported homework problems in the MTA study: evidence for sustained improvement with behavioral treatment. J Clin Child Adolesc Psychol (2010) 1.31
Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment study of Children With ADHD (MTA): part I: executive summary. J Atten Disord (2008) 1.27
Cost-effectiveness of ADHD treatments: findings from the multimodal treatment study of children with ADHD. Am J Psychiatry (2005) 1.26
Acute and long-term safety and tolerability of risperidone in children with autism. J Child Adolesc Psychopharmacol (2005) 1.24
The Treatment for Adolescents With Depression Study (TADS): outcomes over 1 year of naturalistic follow-up. Am J Psychiatry (2009) 1.24
Clinical presentation of attention-deficit/hyperactivity disorder in preschool children: the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). J Child Adolesc Psychopharmacol (2007) 1.24
The transition to middle school is associated with changes in the developmental trajectory of ADHD symptomatology in young adolescents with ADHD. J Clin Child Adolesc Psychol (2008) 1.24
Socioeconomic status as a moderator of ADHD treatment outcomes. J Am Acad Child Adolesc Psychiatry (2002) 1.23
Association of FKBP5 polymorphisms with suicidal events in the Treatment of Resistant Depression in Adolescents (TORDIA) study. Am J Psychiatry (2009) 1.21
Effects of short- and long-term risperidone treatment on prolactin levels in children with autism. Biol Psychiatry (2006) 1.18
Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment Study of children with ADHD (MTA): Part II: supporting details. J Atten Disord (2008) 1.18
Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data. Am J Psychiatry (2004) 1.16
Acute time to response in the Treatment for Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry (2006) 1.16
Substance use and the treatment of resistant depression in adolescents. J Am Acad Child Adolesc Psychiatry (2009) 1.16
Moderators, mediators, and other predictors of risperidone response in children with autistic disorder and irritability. J Child Adolesc Psychopharmacol (2010) 1.15
AACAP 2001 research forum: challenges and recommendations regarding recruitment and retention of participants in research investigations. J Am Acad Child Adolesc Psychiatry (2004) 1.15
Sources of site differences in the efficacy of a multisite clinical trial: the Treatment of SSRI-Resistant Depression in Adolescents. J Consult Clin Psychol (2009) 1.15
Review of safety assessment methods used in pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry (2003) 1.13
A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents. Arch Gen Psychiatry (2012) 1.13
Treatment of early-onset schizophrenia spectrum disorders (TEOSS): rationale, design, and methods. J Am Acad Child Adolesc Psychiatry (2007) 1.09
Treatment of early-onset schizophrenia spectrum disorders (TEOSS): demographic and clinical characteristics. J Am Acad Child Adolesc Psychiatry (2007) 1.08
Sequential pharmacotherapy for children with comorbid attention-deficit/hyperactivity and anxiety disorders. J Am Acad Child Adolesc Psychiatry (2005) 1.05
Effects of risperidone and parent training on adaptive functioning in children with pervasive developmental disorders and serious behavioral problems. J Am Acad Child Adolesc Psychiatry (2011) 1.05
Nine months of multicomponent behavioral treatment for ADHD and effectiveness of MTA fading procedures. J Abnorm Child Psychol (2004) 1.03
Exploring the manifestations of anxiety in children with autism spectrum disorders. J Autism Dev Disord (2013) 1.02
Pubertal delay in male nonhuman primates (Macaca mulatta) treated with methylphenidate. Proc Natl Acad Sci U S A (2011) 1.02
Parent versus teacher ratings of attention-deficit/hyperactivity disorder symptoms in the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). J Child Adolesc Psychopharmacol (2007) 1.01
Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures. Biol Psychiatry (2007) 1.00
A manual-based intervention to address clinical crises and retain patients in the Treatment of Adolescents With Depression Study (TADS). J Am Acad Child Adolesc Psychiatry (2007) 0.99
Brief Report: social disability in autism spectrum disorder: results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network trials. J Autism Dev Disord (2013) 0.98
Factor structure of parent- and teacher-rated attention-deficit/hyperactivity disorder symptoms in the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). J Child Adolesc Psychopharmacol (2007) 0.97
The role of anxiety symptoms in school performance in a community sample of children and adolescents. BMC Public Health (2007) 0.97
Selective serotonin reuptake inhibitors in pediatric depression: is the balance between benefits and risks favorable? J Child Adolesc Psychopharmacol (2006) 0.97
Treatment-related changes in objectively measured parenting behaviors in the multimodal treatment study of children with attention-deficit/hyperactivity disorder. J Consult Clin Psychol (2006) 0.96
Antidepressant exposure as a predictor of clinical outcomes in the Treatment of Resistant Depression in Adolescents (TORDIA) study. J Clin Psychopharmacol (2011) 0.96
Relative cost-effectiveness of treatments for adolescent depression: 36-week results from the TADS randomized trial. J Am Acad Child Adolesc Psychiatry (2009) 0.96
Trial design challenges when combining medication and parent training in children with pervasive developmental disorders. J Autism Dev Disord (2008) 0.96
Examination of aggression and self-injury in children with autism spectrum disorders and serious behavioral problems. Child Adolesc Psychiatr Clin N Am (2014) 0.94
A prospective open trial of guanfacine in children with pervasive developmental disorders. J Child Adolesc Psychopharmacol (2006) 0.94
Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study. J Am Acad Child Adolesc Psychiatry (2010) 0.94
Obsessive-compulsive traits in children and adolescents with Asperger syndrome. Eur Child Adolesc Psychiatry (2009) 0.94
Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity. J Autism Dev Disord (2008) 0.94
Achievement and maintenance of sustained response during the Treatment for Adolescents With Depression Study continuation and maintenance therapy. Arch Gen Psychiatry (2008) 0.93
Factors associated with recruitment and screening in the Treatment for Adolescents With Depression Study (TADS). J Am Acad Child Adolesc Psychiatry (2007) 0.93
Incremental cost-effectiveness of combined therapy vs medication only for youth with selective serotonin reuptake inhibitor-resistant depression: treatment of SSRI-resistant depression in adolescents trial findings. Arch Gen Psychiatry (2011) 0.93
Impact of physical and sexual abuse on treatment response in the Treatment of Resistant Depression in Adolescent Study (TORDIA). J Am Acad Child Adolesc Psychiatry (2011) 0.93
Safeguarding children's rights in psychopharmacological research: ethical and legal issues. Curr Pharm Des (2010) 0.92
National trends in concomitant psychotropic medication with stimulants in pediatric visits: practice versus knowledge. J Atten Disord (2004) 0.92
Assessment of safety and long-term outcomes of initial treatment with placebo in TADS. Am J Psychiatry (2009) 0.92